AB0314 SEMAPHORIN 3A LEVELS IN LUPUS WITH AND WITHOUT SECONDARY ANTIPHOSPHOLIPID ANTIBODY SYNDROME AND RENAL INVOLVEMENT
Background:In this study, we aimed to evaluate sema3A levels in SLE patients with and without renal involvementor secondary antiphospholipid antibody syndrome (APS), to further elucidate the contribution ofsema3A in etiopathogenesis these conditionsObjectives:Aim of this study is to evaluate sema3A levels in systemic lupus erythematosus patients (SLE) with and without renal involvement and secondary antiphospholipid antibody syndrome (APS).Methods:SLE patients were grouped according to presence of secondary APS or renal involvement. The control group consisted of age-matched, non-smoker, healthy volunteers. Sema3A levels were compared among groups. All SLE patients were regrouped according to presence of thrombotic events, miscarriages and proteinuria and sema3A levels were investigated. Finally, sema3A levels of all SLE patients as a single group were compared to controls.Results:The mean sema3A values were 16.16±2.84 ng/dL in the control group, 11.28±5.23 ng/dL in SLE patients without nephritis and APS, 9.05±5.65 ng/dL in SLE with APS group, and 8.53±5.11 ng/dL in lupus nephritis group. When all three patient groups were examined as a single group, mean sema3A value was significantly lower than that of the control group. Sema3A was reduced in SLE patients with thromboembolism and/or miscarriage.Conclusion:Sema3A levels were lower in all patient groups compared to the control group. Moreover, the reduced sema3A levels in patients with a history of thromboembolism and/or miscarriage suggests that sema3A may play an important role in the pathogenesis of vasculopathyTable 1.Comparison of sema3A levels between SLE patient groups and control subjectsPatient groupspGroup A (N=20)Group B (N=20)Group C (N=19)Control (N=19)Sema3A, ng/dL, mean ± SD9.05 ± 5.6511.28 ± 5.238.53 ± 5.1116.16 ± 2.84Group A vscontrol<0.001Group B vscontrol<0.001Group C vscontrol<0.001Group A vs B = 0.203Group A vs C = 0.766Group B vs C = 0.106<0.001All patients (N=59)Control (N=19)9.64 ± 5.3816.16 ± 2.84Patients with thrombotic events and/or miscarriages (N=31)Patients without thrombotic events and/or miscarriages (N=48)0.0329.96 ± 5.1112.33 ± 5.84<0.001Patients with proteinuria and/or thrombotic events and/or miscarriages (N=45)Patients without proteinuria and/or thrombotic events and/or miscarriages (N=34)9.05 ± 5.0914.91± 4.50Disclosure of Interests:None declared